GlassScriptPhysician profile
Anna M Kambic
NPI 1942262456
$5,744.68
in general payments reported to CMS, 2019-2025
29 companies · $14.14 in 2025
The $14.14 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,483 · 2022: $2,369 · 2023: $837 · 2024: $40.33 · 2025: $14.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $755.49 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $704.81 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $652.57 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $552.37 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $357.82 | 2021-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $266.72 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $247.39 | 2021-2023 | Mounjaro |
| Abbott Laboratories | $232.57 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $219.76 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.83 | 2021-2022 | |
| Pfizer INC. | $187.77 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $173.00 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $128.71 | 2022 | |
| Merck Sharp & Dohme LLC | $128.40 | 2021-2023 | Belsomra, Steglatro, Rotateq |
| Bayer Healthcare Pharmaceuticals INC. | $127.51 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $115.82 | 2021-2023 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $97.70 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $79.01 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $77.51 | 2021 | |
| Ibsa Pharma INC. | $74.83 | 2022-2023 | Tirosint, Licart |
| Kowa Pharmaceuticals America, INC. | $58.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.92 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.37 | 2021 | |
| Sanofi Pasteur INC. | $49.74 | 2023 | |
| Dexcom, INC. | $34.76 | 2022 | |
| Alnylam Pharmaceuticals INC. | $30.73 | 2022-2023 | Givlaari |
| Philips North America LLC | $30.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $26.30 | 2023 | Rexulti |
| Tactile Systems Technology INC | $18.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kambic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.